5.25
price up icon38.49%   1.4591
after-market 시간 외 거래: 5.16 -0.09 -1.71%
loading
전일 마감가:
$3.7909
열려 있는:
$5.87
하루 거래량:
36.44M
Relative Volume:
63.01
시가총액:
$11.72B
수익:
-
순이익/손실:
$-60.61M
주가수익비율:
-5.8333
EPS:
-0.9
순현금흐름:
$-22.91M
1주 성능:
+43.44%
1개월 성능:
+63.04%
6개월 성능:
+1,668%
1년 성능:
+540.40%
1일 변동 폭
Value
$4.90
$7.7699
1주일 범위
Value
$3.43
$7.7699
52주 변동 폭
Value
$0.0815
$7.7699

Bioline Rx Ltd Adr Stock (BLRX) Company Profile

Name
명칭
Bioline Rx Ltd Adr
Name
전화
-
Name
주소
-
Name
직원
28
Name
트위터
Name
다음 수익 날짜
2025-03-26
Name
최신 SEC 제출 서류
Name
BLRX's Discussions on Twitter

BLRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BLRX
Bioline Rx Ltd Adr
5.25 13.62M 0 -60.61M -22.91M -0.90
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2017-05-18 업그레이드 Maxim Group Hold → Buy
2017-02-13 개시 Rodman & Renshaw Buy
2016-08-12 다운그레이드 Maxim Group Buy → Hold
2015-08-17 재확인 Maxim Group Buy
2015-07-27 재확인 ROTH Capital Buy
2015-06-22 개시 JMP Securities Mkt Outperform
모두보기

Bioline Rx Ltd Adr 주식(BLRX)의 최신 뉴스

pulisher
05:35 AM

BioLineRx ADR: Positive Earnings Call Highlights and Challenges - MSN

05:35 AM
pulisher
08:46 AM

BioLineRx upgraded to Buy from Hold at JonesResearch - Yahoo Finance

08:46 AM
pulisher
May 30, 2025

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating By Stocktwits - Investing.com India

May 30, 2025
pulisher
May 30, 2025

BioLineRx announces new data from Phase 2 combination trial of motixafortide - TipRanks

May 30, 2025
pulisher
May 30, 2025

Jones Trading raises BioLineRx stock rating, targets $12 By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 30, 2025

Jones Trading raises BioLineRx stock rating, targets $12 - Investing.com

May 30, 2025
pulisher
May 30, 2025

BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial - TipRanks

May 30, 2025
pulisher
May 30, 2025

BioLineRx reports promising pancreatic cancer trial data By Investing.com - Investing.com India

May 30, 2025
pulisher
May 30, 2025

BioLineRx reports promising pancreatic cancer trial data - Investing.com

May 30, 2025
pulisher
May 28, 2025

Jones Trading maintains Hold on BioLineRx stock amid royalty prospects By Investing.com - Investing.com India

May 28, 2025
pulisher
May 28, 2025

H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock - Investing.com

May 28, 2025
pulisher
May 28, 2025

BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks

May 28, 2025
pulisher
May 27, 2025

BioLineRx Ltd. Reports Q1 2025 Financial Results - TipRanks

May 27, 2025
pulisher
May 27, 2025

BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident By Stocktwits - Investing.com India

May 27, 2025
pulisher
May 27, 2025

BioLineRx Reports Q1 2025 Financial Results and Strategic Updates - TipRanks

May 27, 2025
pulisher
May 27, 2025

Options Volatility and Implied Earnings Moves Today, May 27, 2025 - TipRanks

May 27, 2025
pulisher
May 23, 2025

BioLineRx Ltd. Schedules Annual Shareholder Meeting for June 2025 - TipRanks

May 23, 2025
pulisher
May 09, 2025

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail

May 09, 2025
pulisher
Apr 01, 2025

BioLineRx stock rating cut to Hold at Jones Trading - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025 - The Globe and Mail

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Options Volatility and Implied Earnings Moves Today, March 31, 2025 - TipRanks

Mar 31, 2025
pulisher
Mar 07, 2025

Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Feb 27, 2025

Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 19, 2025

BLRX: Aphexda Transition Progressing - Research Tree

Feb 19, 2025
pulisher
Jan 31, 2025

BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com India

Jan 31, 2025
pulisher
Jan 21, 2025

BioLineRx announces strategic shift with licensing deals - Investing.com

Jan 21, 2025
pulisher
Jan 21, 2025

BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks

Jan 21, 2025
pulisher
Jan 17, 2025

BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing - TipRanks

Jan 17, 2025
pulisher
Jan 17, 2025

BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 - Stock Titan

Jan 17, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 07, 2025

BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks

Jan 07, 2025
pulisher
Jan 06, 2025

BioLineRx stock plunges to 52-week low of $0.19 amid market challenges - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks

Jan 06, 2025
pulisher
Jan 06, 2025

BioLineRx Raises $10M in Direct Offering at $0.20 Per ADS with Matching Warrants - Stock Titan

Jan 06, 2025
pulisher
Dec 16, 2024

BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com

Dec 16, 2024
pulisher
Dec 06, 2024

BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com India

Dec 06, 2024
pulisher
Nov 26, 2024

BioLineRx stock target cut, retains buy on Q3 financial results - Investing.com

Nov 26, 2024
pulisher
Nov 25, 2024

BioLineRx Reports Strategic Moves in Q3 2024 - TipRanks

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx earnings beat by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa

Nov 25, 2024
pulisher
Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts By Investing.com - Investing.com South Africa

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks

Nov 25, 2024
pulisher
Nov 22, 2024

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance

Nov 22, 2024

Bioline Rx Ltd Adr (BLRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
자본화:     |  볼륨(24시간):